SCHEMBL22101368

SCHEMBL22101368

CCc1nc2ccc(NC(C)(C)C(=O)O)cn2c(=O)c1O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
HDAC1 Q13547 2/20 0.32
MCHR1 Q99705 2/20 0.32
KDM4E B2RXH2 3/20 0.32
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
AKR1B1 P15121 1/20 0.32
HPGD P15428 3/20 0.31
ALDH1A1 P00352 2/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
TP53 P04637 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HCRTR1 O43613 1/20 0.31
KDM5A P29375 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22101372 0.88 HDAC1 (0.35) MAPTRXFP1HDAC1MCHR1KDM4E
SCHEMBL22101371 0.86 RXFP1 (0.35) MAPTRXFP1HDAC1MCHR1KDM4E
SCHEMBL22101373 0.86 KDM4E (0.38) MAPTRXFP1HDAC1MCHR1KDM4E
SCHEMBL22101390 0.80 MAPT (0.33) MAPT
SCHEMBL22101340 0.79 TP53 (0.41) MAPTRXFP1KDM4EGAAHPGD
SCHEMBL22101405 0.78 HDAC1 (0.31) HDAC1KDM4EGLAGAA
SCHEMBL22101810 0.77 HDAC1 (0.34) MAPTRXFP1HDAC1MCHR1KDM4E
SCHEMBL22393760 0.76 MAP3K5 (0.35) MAPTRXFP1HDAC1KDM4EGLA
SCHEMBL22101183 0.74 KDM4E (0.50) MAPTRXFP1KDM4EGLAGAA
SCHEMBL22393791 0.71 ADORA3 (0.39) MAPTKDM4EHPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230035184-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-02-02 US disclosed
US-11332465-B2 Diarylthiohydantoin compound as androgen receptor antagonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-05-17 US disclosed
US-20200277290-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-09-03 US disclosed
EP-3666772-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230035184-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST AR, NR5A1, LHCGR MAPT 4384/4885RXFP1 721/4885HDAC1 409/4885
US-20200277290-A1 DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST AR, NR5A1, LHCGR MAPT 4384/4885RXFP1 721/4885HDAC1 409/4885
US-11332465-B2 Diarylthiohydantoin compound as androgen receptor antagonist AR, NR5A1, LHCGR MAPT 4384/4885RXFP1 721/4885HDAC1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.